The metabolic memory phenomenon in predicting a risk for vascular complications in diabetes mellitus

Cite item

Full Text


The paper presents data on positive and negative metabolic memory phenomena in patients with type 1 and type 2 diabetes mellitus (DM) as exemplified by the long-term randomized trials DCCT, UKPDS, ACCORD, VADT, and ADVANCE. It discusses the role of metabolic memory in predicting a risk for vascular complications in DM. Ideas on the mechanisms of this phenomenon, which are based on the activation of oxidative stress, the production of irreversible glycation products, and epigenetic disorders, are given.

About the authors

I I Dedov

M V Shestakova


  1. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-983.
  2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
  3. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-812.
  4. Тhe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:683-689.
  5. Nathan David M. for the DCCT/EDIC Research group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014;37:9-16.
  6. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of retinopathy at 20 years after onset in younger-onset type 1 diabetes using mean metabolic memory-free HbA1c values. Diabetes Care. 2013;36(11):3812-3814.
  7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359:1577-1589.
  8. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358:2545-2559.
  9. Duckworth W, Abraira C, Moritz T et al. for the VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360:129-139.
  10. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC; ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649-159.
  11. Fioretto P., Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69-75.
  12. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-2206.
  13. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358:2560-2572.
  14. Zoungas S, Chalmers J, Neal B, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406.
  15. Ceriello A, Ihnat MA, Thorpe JE. The «metabolic memory»: is more than just tight glucose control nessesary to prevent diabetic complications? J Clin Metab. 2009;94:410-415.
  16. Титов В.Н., Ширяева Ю.Н. Глюкоза, гликотоксины и продукты гликирования. Участие в патогенезе микроангиопатий, артериолосклероза и атеросклероза. Клиническая лабораторная диагностика. 2011;11:3-13.
  17. Cencioni C, Spallotta F, Greco S, Martelli F, Zeiher AM., Gaetano C. Epigenetic mechanisms of hyperglycemic memory. Int J Biochem Cell Biol. 2014;51:155-158.
  18. Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic «memory» induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev. 2008;24:301-309.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies